About Zenotech Laboratories
Zenotech Laboratories is a publicly listed company based in Hyderabad (India) founded in 1989, and was acquired by Sun Pharma in July 2017. Generic injectables for oncology and anesthesiology are manufactured. The company has 228 employees. Its chief executive, as recorded, is Rajendra Singh Parihar. Its Indian entity Zenotech Laboratories Limited reported revenue of ₹45.92 Cr. Its focus areas include Traditional Pharmaceuticals, Generics, Injectables and Oncology.
Company details
Zenotech Laboratories was established in 1989 in Hyderabad, India, within the pharmaceutical sector. Generic injectables are produced by the company, with a focus on therapy areas including oncology and anesthesiology. Specific products such as granulocyte-colony stimulating factor (GCSF) and granulocyte-macrophage-colony-stimulating factor (GMCSF) are offered. Operations center on manufacturing these formulations for medical applications.
- Headquarters Hyderabad, India
- Employees 228
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website zenotechlab.com
- Social LinkedIn
- Acquired by Sun Pharma (Jul 2017)
- Legal Name Zenotech Laboratories Limited
- Market Cap₹234 Cr
ZENOTECH · BSE
- Share Price₹38.50
+0.23% today
- Revenue₹43.61 Cr
FY 2025-26 · +1.3% YoY
- EBITDA₹8.98 Cr
Margin 20.6%
- Net Profit−₹1.11 Cr
FY 2025-26 · -138.5% YoY
- Investors
- Employee Count228
- Acquired bySun Pharma
(Jul 2017)
Associated legal entities of Zenotech Laboratories
Zenotech Laboratories operates through Zenotech Laboratories Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Zenotech Laboratories Limited Listed CIN L27100TG1989PLC010122 | Active | 15 Jun 1989 | Hyderabad, Telangana | ₹45.9 Cr | 181 | 9 | View details |
Investors in Zenotech Laboratories
Zenotech Laboratories has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sun Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | sunpharma.com | Mumbai, India |
Investor details for Zenotech Laboratories
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Zenotech Laboratories Limited (Zenotech Laboratories)
Zenotech Laboratories Limited is the primary company behind Zenotech Laboratories. The board of Zenotech Laboratories Limited currently have 6 directors; the longest-serving is Jignesh Anantray Goradia, appointed in 2015. 38 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jignesh Anantray Goradia DIN 07229899 | Director | 08 Jul 2015 | 11 yrs 4 mo | Zenotech Laboratories Limited |
| Azadar Husain Asghar Mehdi Khan DIN 01219312 | Director | 25 Aug 2015 | 11 yrs 2 mo | Zenotech Laboratories Limited |
| Jagruti Prashant Sheth DIN 07129549 | Director | 01 Feb 2020 | 6 yrs 9 mo | Zenotech Laboratories Limited |
| Rakeshchandra Jagdishprasad Sinha DIN 07340998 | Director | 01 Feb 2020 | 6 yrs 9 mo | Zenotech Laboratories Limited |
| Premal Hemant Gandhi DIN 09668275 | Director | 28 Jan 2025 | 1 yr 9 mo | Zenotech Laboratories Limited |
| Nikkhil Venilal Kothhari DIN 11501373 | Director | 23 Jan 2026 | 9 mo | Zenotech Laboratories Limited |
People of Zenotech Laboratories
2 people are tracked at Zenotech Laboratories (2 in leadership); the tracked headcount is 228.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership | |
Rajendra Singh Parihar | CEO | Leadership |
Complete people profiles for Zenotech Laboratories
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Zenotech Laboratories
Zenotech Laboratories is a publicly listed company on the BSE with ticker symbol ZENOTECH in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Mar 2004
- Listed onBOM: 532039
- Listed entityZenotech Laboratories Limited
- Exchange sectorHealth technology
- ISININE486F01012
- Share price₹43.99 (+0.76% on the day) · 2026-10-14
- Market capitalisation₹266 Cr
- Price to earnings92.3
- EPS (diluted, trailing year)₹-0.41
- Volume (last session)1,684
Financials of Zenotech Laboratories
Exchange-reported figures of Zenotech Laboratories Limited, the listed company behind Zenotech Laboratories (BSE: ZENOTECH).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 43.61 | 43.05 | 40.83 | 42.42 | 36.57 | 22.45 | 26.02 |
| Revenue growth | +1.3% | +5.4% | -3.8% | +16.0% | +62.9% | -13.7% | - |
| EBITDA | 8.98 | 14.18 | 17.22 | 20.71 | 17.46 | 6.39 | 8.99 |
| EBITDA margin | +20.6% | +32.9% | +42.2% | +48.8% | +47.7% | +28.5% | +34.6% |
| Profit before tax | 4.18 | 10.69 | 11.13 | 14.51 | 9.90 | (1.21) | 10.79 |
| Net profit | (1.11) | 2.88 | 8.32 | 11.56 | 22.17 | (1.21) | 4.42 |
| Net profit margin | -2.6% | +6.7% | +20.4% | +27.3% | +60.6% | -5.4% | +17.0% |
| EPS (₹) | (0.18) | 0.92 | 1.36 | 1.90 | 3.63 | (0.20) | 1.77 |
| Balance sheet | |||||||
| Total assets | 98.27 | 98.44 | 92.68 | 84.27 | 78.51 | 70.90 | 71.54 |
| Net worth | 95.12 | 96.13 | 90.54 | 82.27 | 70.64 | 48.41 | 49.63 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 20.66 | 21.42 |
| Cash & bank | 30.42 | 26.70 | 19.69 | 11.14 | 2.41 | 2.46 | 1.12 |
| Net working capital | 28.99 | 23.40 | 12.65 | (0.34) | (8.21) | (7.61) | (8.32) |
| Cash flow | |||||||
| Cash from operations | 10.20 | 9.54 | 11.82 | 20.66 | 17.67 | 5.74 | 11.38 |
| Cash from investing | (6.49) | 15.21 | (21.15) | (5.82) | (1.84) | (4.82) | (20.79) |
| Cash from financing | 0.00 | 0.00 | 0.00 | (6.11) | (15.87) | 0.45 | (2.70) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.15 | 10.62 | 9.89 | 12.86 | 11.23 | 9.64 | 12.13 | 11.24 |
| Revenue growth (YoY) | -36.3% | +10.2% | -18.5% | +14.4% | +14.9% | -2.7% | - | - |
| Other income | 0.42 | 0.44 | 0.65 | 0.42 | 0.75 | 0.59 | 0.49 | 1.00 |
| Total expenses | 9.18 | 9.75 | 9.71 | 8.89 | 8.95 | 7.18 | 7.71 | 7.37 |
| EBITDA | (2.03) | 0.87 | 0.18 | 3.97 | 2.28 | 2.46 | 4.42 | 3.87 |
| EBITDA margin | -33.1% | +9.1% | +2.0% | +33.6% | +22.3% | +28.5% | +39.8% | +37.9% |
| Depreciation | 1.82 | 1.90 | 1.76 | 1.80 | 1.78 | 1.77 | 1.73 | 1.76 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (3.43) | (0.59) | (0.93) | 2.59 | 1.25 | 1.28 | 3.18 | 3.11 |
| Tax | (0.85) | (0.15) | 2.21 | 0.66 | 2.09 | 0.29 | 1.95 | 1.42 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7.15 | 10.62 | 9.89 | 12.86 | 11.23 | 9.64 | 12.13 | 11.24 |
| Revenue growth (YoY) | -36.3% | +10.2% | -18.5% | +14.4% | +14.9% | -2.7% | - | - |
| Other income | 0.42 | 0.44 | 0.65 | 0.42 | 0.75 | 0.59 | 0.49 | 1.00 |
| Total expenses | 9.18 | 9.75 | 9.71 | 8.89 | 8.95 | 7.18 | 7.71 | 7.37 |
| EBITDA | (2.03) | 0.87 | 0.18 | 3.97 | 2.28 | 2.46 | 4.42 | 3.87 |
| EBITDA margin | -33.1% | +9.1% | +2.0% | +33.6% | +22.3% | +28.5% | +39.8% | +37.9% |
| Depreciation | 1.82 | 1.90 | 1.76 | 1.80 | 1.78 | 1.77 | 1.73 | 1.76 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (3.43) | (0.59) | (0.93) | 2.59 | 1.25 | 1.28 | 3.18 | 3.11 |
| Tax | (0.85) | (0.15) | 2.21 | 0.66 | 2.09 | 0.29 | 1.95 | 1.42 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 43.61 | 43.05 | 40.83 | 42.42 | 36.57 | 22.45 | 26.02 |
| Revenue growth | +1.3% | +5.4% | -3.8% | +16.0% | +62.9% | -13.7% | - |
| Other income | 2.31 | 3.47 | 1.00 | 1.08 | 0.63 | 0.41 | 7.54 |
| Total expenses | 34.63 | 28.87 | 23.61 | 21.71 | 19.11 | 16.06 | 17.03 |
| Employee cost | 15.53 | 12.38 | 9.46 | 7.88 | 7.10 | 6.49 | 5.76 |
| EBITDA | 8.98 | 14.18 | 17.22 | 20.71 | 17.46 | 6.39 | 8.99 |
| EBITDA margin | +20.6% | +32.9% | +42.2% | +48.8% | +47.7% | +28.5% | +34.6% |
| Depreciation | 7.11 | 6.96 | 7.09 | 7.17 | 6.97 | 6.46 | 4.85 |
| Interest | 0.00 | 0.00 | 0.00 | 0.11 | 1.22 | 1.55 | 0.89 |
| Profit before tax | 4.18 | 10.69 | 11.13 | 14.51 | 9.90 | (1.21) | 10.79 |
| Tax | 5.26 | 5.08 | 2.84 | 2.92 | (12.27) | 0.00 | 0.00 |
| Net profit | (1.11) | 2.88 | 8.32 | 11.56 | 22.17 | (1.21) | 4.42 |
| Net profit margin | -2.6% | +6.7% | +20.4% | +27.3% | +60.6% | -5.4% | +17.0% |
| EPS (₹) | (0.18) | 0.92 | 1.36 | 1.90 | 3.63 | (0.20) | 1.77 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 | 61.03 |
| Reserves & surplus | 34.09 | 35.10 | 29.51 | 21.24 | 9.61 | (12.62) | (11.40) |
| Shareholders' funds (net worth) | 95.12 | 96.13 | 90.54 | 82.27 | 70.64 | 48.41 | 49.63 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 20.66 | 21.42 |
| Total debt | 0.00 | 0.00 | 0.00 | 0.00 | 6.00 | 20.66 | 21.42 |
| Total liabilities | 98.27 | 98.44 | 92.68 | 84.27 | 78.51 | 70.90 | 71.54 |
| Assets | |||||||
| Gross block | 125 | 116 | 114 | 107 | 105 | 101 | 69.52 |
| Net block | 62.29 | 60.86 | 65.58 | 65.39 | 70.91 | 74.23 | 48.73 |
| Capital work in progress | 3.60 | 3.57 | 1.96 | 4.98 | 0.28 | 2.18 | 29.08 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.84 | 0.00 | 0.06 | 0.06 | 0.09 |
| Sundry debtors | 8.78 | 7.45 | 3.25 | 3.32 | 3.93 | 3.80 | 1.86 |
| Cash & bank balances | 30.42 | 26.70 | 19.69 | 11.14 | 2.41 | 2.46 | 1.12 |
| Loans & advances | 1.84 | 1.64 | 2.39 | 1.80 | 0.97 | 1.02 | 2.63 |
| Total current assets | 41.04 | 35.79 | 26.17 | 16.26 | 7.37 | 7.34 | 5.70 |
| Total current liabilities | 12.05 | 12.39 | 13.52 | 16.60 | 15.58 | 14.95 | 14.02 |
| Net working capital | 28.99 | 23.40 | 12.65 | (0.34) | (8.21) | (7.61) | (8.32) |
| Total assets | 98.27 | 98.44 | 92.68 | 84.27 | 78.51 | 70.90 | 71.54 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 26.58 | 1.82 | 11.14 | 2.41 | 2.46 | 1.08 | 13.20 |
| Net cash from operating activities | 10.20 | 9.54 | 11.82 | 20.66 | 17.67 | 5.74 | 11.38 |
| Net cash from investing activities | (6.49) | 15.21 | (21.15) | (5.82) | (1.84) | (4.82) | (20.79) |
| Net cash from financing activities | 0.00 | 0.00 | 0.00 | (6.11) | (15.87) | 0.45 | (2.70) |
| Net change in cash | 3.71 | 24.76 | (9.33) | 8.73 | (0.04) | 1.38 | (12.11) |
| Closing cash | 30.42 | 26.70 | 19.69 | 11.14 | 2.41 | 2.46 | 1.12 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +1.3% | +5.4% | -3.8% | +16.0% | +62.9% | -13.7% | - |
| EBITDA growth | -36.7% | -17.7% | -16.9% | +18.6% | +173.2% | -28.9% | - |
| PBT growth | -60.9% | -4.0% | -23.3% | +46.6% | +9998.0% | - | +9998.0% |
| Net income growth | -138.5% | -65.4% | -28.0% | -47.9% | +1932.2% | -127.4% | - |
| Revenue CAGR (3Y) | +0.9% | +5.6% | +22.1% | +17.7% | +41.1% | +26.3% | +126.1% |
| EBITDA CAGR (3Y) | -24.3% | -6.7% | +39.2% | +32.1% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | -2.5% | +13.0% | +20.3% | +27.3% | +60.6% | -5.4% | +41.5% |
| Return on capital employed | 0.0% | +3.2% | +4.1% | +5.3% | +6.4% | 0.0% | +3.0% |
| Return on net worth | 0.0% | +1.1% | +3.1% | +4.3% | +13.9% | 0.0% | +2.9% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.22 | 0.43 | 0.47 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.22 | 0.21 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.81 | 11.63 | -2,214.29 | 21.50 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.36 | 0.37 | 0.37 | 0.40 | 0.35 | 0.26 | 0.40 |
| Inventory turnover | 0.00 | 102.50 | 97.21 | 1,414.00 | 609.50 | 299.33 | 77.67 |
| Debtors turnover | 5.37 | 8.05 | 12.43 | 11.70 | 9.46 | 7.93 | 12.33 |
| EPS (₹) | (0.18) | 0.92 | 1.36 | 1.90 | 3.63 | (0.20) | 1.77 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 15.59 | 15.75 | 14.84 | 13.48 | 11.57 | 7.93 | 8.13 |
Timeline of Zenotech Laboratories
3 dated milestones of Zenotech Laboratories across 28 years, from founding to its latest funding, stage changes and deals.
- Founded Zenotech Laboratories is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Sun Pharma.
Web traffic of Zenotech Laboratories
The website of Zenotech Laboratories (zenotechlab.com) receives about 6.4K visits a month.
- Monthly visits6.4K
▲ 486.3% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zenotech Laboratories
Complete news archive for Zenotech Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zenotech Laboratories
Zenotech Laboratories was founded in 1989.
Zenotech Laboratories is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Rajendra Singh Parihar is the CEO of Zenotech Laboratories, as recorded in our data.
Zenotech Laboratories has 228 employees.
The primary company behind Zenotech Laboratories, Zenotech Laboratories Limited, reported revenue of ₹45.92 Cr for FY 2026, up 1% year on year.
Zenotech Laboratories was established in 1989 in Hyderabad, India, within the pharmaceutical sector. Generic injectables are produced by the company, with a focus on therapy areas including oncology and anesthesiology. Specific products such as granulocyte-colony stimulating factor (GCSF) and granulocyte-macrophage-colony-stimulating factor (GMCSF) are offered. Operations center on manufacturing these formulations for medical applications.
Yes, Zenotech Laboratories is publicly traded on BSE under the ticker symbol ZENOTECH.
Zenotech Laboratories has 1 investor. Key investors include Sun Pharma.
Zenotech Laboratories operates through Zenotech Laboratories Limited.
Yes. Zenotech Laboratories was acquired by Sun Pharma in July 2017.
The legal entities of Zenotech Laboratories currently have 9 directors, including Abdul Gafoor Mohammad, Azadar Husain Asghar Mehdi Khan, Jignesh Anantray Goradia and others.